Cardioprotection Afforded by St Thomas Solution Is Enhanced by Emulsified Isoflurane in an Isolated Heart Ischemia Reperfusion Injury Model in Rats

Huang, Han; Zhang, Wensheng; Liu, Shanling; Chen, Yanfang; Li, Tao; Liu, Jin

doi:10.1053/j.jvca.2009.10.016

“…More importantly, emulsion is critical in this protective process. There is evidence that intravenous emulsion therapy has a positive effect on hemodynamics (37,38), and it protects the heart by decreasing apoptosis (39,40). In the experiments of the present study, MAP at 30 and 60 min after ROSC in the E group was the highest among five groups, and memory function and survival rate at 1 day after ROSC in the E group were better compared with the control group, although these differences were not statistically significant.…”

Section: Discussioncontrasting

confidence: 58%

Emulsified isoflurane postconditioning improves survival and neurological outcomes in a rat model of cardiac arrest

Zhang

¹

,

Yu

²

2014

European Journal of Anaesthesiology

0

View full text Add to dashboard Cite

Emulsified isoflurane (EIso) has a protective effect against ischemia/reperfusion (I/R) injury in animal models. However, the protective effects of EIso on global cerebral I/R injury remain unclear. The present study aimed to investigate whether EIso postconditioning was able to improve survival and neurological outcomes in a rat model of cardiac arrest (CA). Rats were randomly divided into five groups, namely the control, EIso-2ml, EIso-4ml, isoflurane (Iso) and emulsion (E) groups. All rats were resuscitated by a standardized method following 6 min of asphyxia. Furthermore, all interventions were administered immediately following the return of spontaneous circulation (ROSC). The animal survival was recorded daily, and evaluations of behavioral and brain morphology were assessed at 1 and 7 days after ROSC. The results showed that EIso treatment increased the survival rate 7 days after ROSC, with a 41.7% 7-day survival in the EIso-2ml group, 66.7% in the EIso-4ml group and 50% in the Iso group compared with 33.3% survival in the control and E groups. Moreover, the neural deficit score and memory function were improved in the EIso-4ml group, and this treatment also ameliorated brain hippocampal cell injury and apoptosis. In addition, a better brain protective effect was observed in the EIso-4ml group compared with the EIso-2ml, Iso and E groups. In summary, the data of the present study suggest that EIso postconditioning improved the survival and neurological outcomes following CA in a dose-dependent manner.

show abstract

“…There is evidence that intravenous emulsion therapy has a positive effect on hemodynamics (37,38), and it protects the heart by decreasing apoptosis (39,40). In the experiments of the present study, MAP at 30 and 60 min after ROSC in the E group was the highest among five groups, and memory function and survival rate at 1 day after ROSC in the E group were better compared with the control group, although these differences were not statistically significant.…”

Section: Discussionmentioning

confidence: 99%

Emulsified isoflurane postconditioning improves survival and neurological outcomes in a rat model of cardiac arrest

Zhang

¹

,

M

²

,

Yu

³

et al. 2017

Experimental and Therapeutic Medicine

Self Cite

View full text Add to dashboard Cite

Emulsified isoflurane (EIso) has a protective effect against ischemia/reperfusion (I/R) injury in animal models. However, the protective effects of EIso on global cerebral I/R injury remain unclear. The present study aimed to investigate whether EIso postconditioning was able to improve survival and neurological outcomes in a rat model of cardiac arrest (CA). Rats were randomly divided into five groups, namely the control, EIso-2ml, EIso-4ml, isoflurane (Iso) and emulsion (E) groups. All rats were resuscitated by a standardized method following 6 min of asphyxia. Furthermore, all interventions were administered immediately following the return of spontaneous circulation (ROSC). The animal survival was recorded daily, and evaluations of behavioral and brain morphology were assessed at 1 and 7 days after ROSC. The results showed that EIso treatment increased the survival rate 7 days after ROSC, with a 41.7% 7-day survival in the EIso-2ml group, 66.7% in the EIso-4ml group and 50% in the Iso group compared with 33.3% survival in the control and E groups. Moreover, the neural deficit score and memory function were improved in the EIso-4ml group, and this treatment also ameliorated brain hippocampal cell injury and apoptosis. In addition, a better brain protective effect was observed in the EIso-4ml group compared with the EIso-2ml, Iso and E groups. In summary, the data of the present study suggest that EIso postconditioning improved the survival and neurological outcomes following CA in a dose-dependent manner.

show abstract

“…St Thomas cardioplegia solution supplemented with emulsified isoflurane enhanced its cardioprotection in an isolated heart ischemia reperfusion injury model in rats [7].…”

Section: Emulsified Isoflurane (Eiso)mentioning

confidence: 92%

Can intralipid infusion open a coronary occlusion causing acute myocardial infarction?

Eldor¹

2017

Clin Med Invest

0

View full text Add to dashboard Cite

Coronary heart disease remains the leading cause of morbidity and mortality in Western countries. The best hope of salvaging viable myocardium after a coronary occlusion is by rapid reperfusion of the ischemic myocardium, either by thrombolysis or primary percutaneous coronary intervention. The use of intravenous intralipid infusion instead of thrombolysis or primary percutaneous coronary intervention is first suggested in the medical literature.Correspondence to: Joseph Eldor, Theoretical Medicine Institute, Jerusalem, Israel, E-mail: csen_international@csen.com Key words: intralipid, myocardial infarction, coronary occlusionReceived: June 18, 2017; Accepted: July 15, 2017; Published: July 17, 2017 Thrombolysis or primary percutaneous coronary intervention or Intralipid Infusion?Coronary heart disease remains the leading cause of morbidity and mortality in Western countries. The best hope of salvaging viable myocardium after a coronary occlusion is by rapid reperfusion of the ischemic myocardium, either by thrombolysis or primary percutaneous coronary intervention. Although reperfusion restores blood flow, oxygen, and nutrients to the cardiac muscle, it also has the potential to induce reperfusion injury.Postconditioning of the heart with brief episodes of reperfusion/ occlusion at the onset of reflow has been shown to limit infarct size. However, this approach is not practical for patients treated with thrombolytic agents and therefore a more generic pharmacologic postconditioning is still needed. The ideal pharmacologic candidates need to be safe and effective when administered during the first few minutes of reperfusion by inducing cellular protection or enhancing myocardial tolerance to ischemia/reperfusion injury. Several drugs have yielded encouraging results in animals and a few have been tested in humans; however, none of these modalities has been widely accepted.Lipids and in particular polyunsaturated fatty acids have received special cardiovascular research attention because polyunsaturated fatty acid-rich diets are associated with a decreased risk of coronary artery disease. Acute application of polyunsaturated fatty acids to cardiomyocytes has also been shown to shorten action potential duration and this could account for the antiarrhythmic mechanism of the polyunsaturated fatty acids. Intralipid (Sigma, St. Louis, MO) is a brand name for the first safe fat emulsion for human use; Intralipid 20% is an emulsion of soybean oil (20%), egg yolk phospholipids (1.2%), and glycerol (2.2%). Intralipid has been widely used in patients who need total parenteral nutrition and as a vehicle for different drugs such as propofol. It has been shown recently that postischemic administration of Intralipid protects the isolated rat heart against ischemia/reperfusion injury. However, the molecular mechanism in which Intralipid mediates cardioprotection is completely unknown [1].Intralipid, a brand name for the first safe fat emulsion for human use, has been shown to be cardioprotective. However, the mechanism ...

show abstract

Cardioprotection Afforded by St Thomas Solution Is Enhanced by Emulsified Isoflurane in an Isolated Heart Ischemia Reperfusion Injury Model in Rats

Cited by 20 publications

References 28 publications

Emulsified isoflurane postconditioning improves survival and neurological outcomes in a rat model of cardiac arrest

Emulsified isoflurane postconditioning improves survival and neurological outcomes in a rat model of cardiac arrest

Emulsified isoflurane postconditioning improves survival and neurological outcomes in a rat model of cardiac arrest

Can intralipid infusion open a coronary occlusion causing acute myocardial infarction?

Contact Info

Product

Resources

About